Galactomannan Antigen Concordance in Bronchoscopic Bronchoalveolar Lavage and Blind Mini Bronchoalveolar Lavage

Main Article Content

Isabel Villanueva
https://orcid.org/0000-0002-7892-2449
Nicolás Arechavaleta
https://orcid.org/0000-0002-4526-024X
Eduardo Quintana
Jimena Nuñez Jimena Nuñez
https://orcid.org/0000-0001-7130-9214
María Pía González
Mauricio Carbia
https://orcid.org/0000-0002-5560-654X
Pablo Alvarez
https://orcid.org/0000-0002-1053-313X
Federico Verga
https://orcid.org/0000-0002-7917-1616
Ana Inés Gruss

Abstract

Introduction: viral pneumonias increase the susceptibility to develop fungal secondary infections. With COVID-19 pandemic, multiple cases of invasive pulmonary aspergillosis associated with COVID-19 (PAAC) have been reported, increasing mortality. It is not recommended to perform bronchoscopy during COVID-19 illness given the risk of aerosolization, so new techniques such as mini bronchoalveolar lavage (BAL) emerge. The necessity to perform a validating task for the galactomannan (GM) measurement in samples obtained through mini-BAL emerges from the absence of cutting points for the GM antigen positivity in respiratory samples non obtained by bronchoscopy. 


Aim: to validate the concordance of GM measurement in respiratory samples obtained through mini-BAL and BAL by bronchoscopy. 


Material and methods: observational and analytical prospective study. Patients admitted to intensive care unit with suspected PAAC who were asked to obtain respiratory samples for MG study were included. In all the cases, BAL and mini-BAL samples were obtained in one same procedure. It was considered positive GM with a value higher than 1. 


Results: 11 patients were studied, 6 (54.5%) cases were diagnosed positive for PAAC through bronchoscopic BAL. The mini-BAL sensitivity was 33% and the specificity 100%; predictive positive value 100% and negative predictive value 55%. The concordance correlation coefficient was 0,28% (IC -0,078 a 0,57), which showed a poor concordance between both methods.


Conclusion: The GM test through mini-BAL could prove to be a fine confirmatory method, while a negative result does not discard PAAC.

Downloads

Download data is not yet available.

Article Details

How to Cite
Villanueva, I., Arechavaleta, N., Quintana, E., Jimena Nuñez, J. N., González, M. P., Carbia, M. ., Alvarez, P., Verga, F., & Gruss, A. I. (2022). Galactomannan Antigen Concordance in Bronchoscopic Bronchoalveolar Lavage and Blind Mini Bronchoalveolar Lavage. Respirar, 14(3), 147–152. https://doi.org/10.55720/14.3.4
Section
Artículos Originales

References

Short KR, Kasper J, Van Der Aa S et al. Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions. Eur Respir J 2016;47:954–66. Doi: 10.1183/13993003.01282-2015

Herold S, Becker C, Ridge KM, Budinger GRS. Influenza virus-induced lung injury: Pathogenesis and implications for treatment. Eur Respir J 2015;45:1463–78. Doi: 10.1183/09031936.00186214

Guan W, Ni Z, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708–20. Doi: 10.1056/NEJMoa2002032.

Bartoletti M, Pascale R, Cricca M et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis 2020;1–35. Doi: 10.1093/cid/ciaa1065

White PL, Rishi D, Cordey A et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis 2020; e1634-e1644

Apostolopoulou A, Garrigos ZE, Vijayvargiya P, Lerner AH, Farmakiotis D. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: A systematic review of the literature. Diagnostics 2020;10:807.

Koehler P, Bassetti M, Chakrabarti A et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021;21:e149–62. Doi: 10.1016/S1473-3099(20)30847-1

Wahidi MM, Lamb C, Murgu S et al. American Association for Bronchology and Interventional Pulmonology (AABIP) Statement on the Use of Bronchoscopy and Respiratory Specimen Collection in Patients with Suspected or Confirmed COVID-19 Infection. J Bronchol Interv Pulmonol 2020;27:e52–4. Doi: 10.1097/LBR.0000000000000681

Neves CP, Costa AG, Safe IP et al. The role of mini-bronchoalveolar lavage fluid in the diagnosis of pulmonary tuberculosis in critically ill patients. BMC Infect Dis 2020;20:1–7. Doi: 10.1186/s12879-020-04954-3

Muñoz L, Gallego C, Joza K et al. Estudio comparativo del rendimiento de GeneXpertMTB/RIF en lavado broncoalveolar frente al lavado bronquial en pacientes con sospecha clínica de tuberculosis. Rev Am Med Respir 2021;21:1–5.

Artuk C, Hanefi CeG, Gurkan M. Comparison of endotracheal aspiration and mini.BAL culture results in the diagnosis of ventilator-associated pneumonia. Mikrobiyol Bul 2012;46:421–31.

Schellenberg M, Inaba K. Pneumonia in Trauma Patients. Curr Trauma Reports 2017;3:308–14.

Lacroix G, Prunet B, Bordes J et al. Evaluation of early mini-bronchoalveolar lavage in the diagnosis of health care-associated pneumonia: A prospective study. Crit Care 2013;17:R24. Doi: 10.1186/cc12501